证券代码：605199 证券简称：葫芦娃 公告编号：2025-047 海南葫芦娃药业集团股份有限公司 关于获得头孢丙烯干混悬剂药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的关于头孢丙烯干混悬剂的《药品注册证书》。 现将有关情况公告如下： 一、药品基本情况 药物名称：头孢丙烯干混悬剂 剂型：口服混悬剂 注册分类：化学药品 3 类 规格：2.5g（按 C₁₈H₁₉N₃O₅S 计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2302198 药品批准文号：国药准字 H20254800 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工 艺照所附执行。 本品上市前需进行药品生产质量管理规范符合性检查。 二、药品研发及相关 头孢丙烯是一种头孢菌素抗生素，原研单位为 Bristol-My ...

7信会计师事务所(特殊普通; O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 立信会计师事务所(特殊普通合伙) 关于对海南葫芦娃药业集团股份有限公司 2024 年年度报告的信息披露监管问询函的回复 信会师函字[2025]第 ZA320 号 上海证券交易所上市公司管理一部: 海南葫芦娃药业集团股份有限公司(以下简称"葫芦姑"或"公司")2025 年 6月13日收到贵部下发的《关于海南葫芦娃药业集团股份有限公司 2024年年 度报告的信息披露监管间询函》(上证公函【2025】第 0838 号)(以下简称"年 报问询函"),立信会计师事务所(特殊普通合伙)(以下简称"本所"或"年审 会计师")作为葫芦娃2024年年报审计机构,对贵部间询函中要求本所发表意见 的事项回复如下: 问题 1:关于差错更正事项。年报及临时公告显示,年审会计师对公司财务 报表出具保留意见,内部控制出具否定意见,涉及公司对 2023年度财务报表进 行差错更正、控股股东向公司客户提供资金支持等事项。2023 年公司部分销售 业务提前确认收入,部分销售业务销售价格异常,以及因提前确认收入产生 ...

海南葫芦娃药业集团股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复公告 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于近期收到上海证 券交易所《关于海南葫芦娃药业集团股份有限公司 2024 年年度报告的信息披露 监管问询函》（上证公函【2025】0838 号）（以下简称"《问询函》"）。公 司对《问询函》涉及的问题进行了逐项核实，现将回复情况公告如下： 问题 1.关于差错更正事项。 年报及临时公告显示，年审会计师对公司财 务报表出具保留意见，内部控制出具否定意见，涉及公司对 2023 年度财务报表 进行差错更正、控股股东向公司客户提供资金支持等事项。2023 年公司部分销 售业务提前确认收入，部分销售业务销售价格异常，以及因提前确认收入产生 对应费用差异，导致公司相关定期报告披露的财务数据不准确。 请公司补充披露：（1）公司提前确认收入对应的客户名称、销售产品类 型、销售收入、更正前后的收入确认时点、确认依据以及对应费用金额、类型、 用途、归属区间的确认标准；（2）公司产品销售价格异常对应的产品名称、调 整前后价格以及对收入的影响，并列明涉及的销售客户情况；（3）控股股东向 公司客户提 ...

Group 1 - The third supervisory board meeting of Hainan Huluwa Pharmaceutical Group Co., Ltd. was held on June 27, 2025, in accordance with relevant laws and regulations [1][2] - The meeting was attended by all three supervisors, and the chairman of the supervisory board presided over the meeting [1][2] - The supervisory board approved the proposal to temporarily use idle raised funds to supplement the company's working capital, which aligns with regulatory requirements and does not affect the normal investment plan of the raised funds [2] Group 2 - The voting results showed unanimous support with 3 votes in favor, 0 abstentions, and 0 votes against [2] - The supervisory board believes that the temporary use of idle funds will enhance the efficiency of fund utilization and is in the best interest of all shareholders [2]

Core Viewpoint - The company has announced a delay in the disclosure of the audit report for correcting prior accounting errors due to the substantial workload involved in the process [1][2] Group 1 - The company's board approved a proposal to correct prior accounting errors in accordance with relevant accounting standards and regulations [1] - The audit work is being actively pursued, but the company is unable to complete it as originally planned due to the extensive nature of the tasks involved [1] - The company expresses apologies for any inconvenience caused to investors during this delay and seeks their understanding [2] Group 2 - The company is enhancing communication and collaboration with the accounting firm, increasing the number of professionals involved to expedite the audit process [2] - The company is committed to adhering to legal and regulatory requirements while ensuring the quality of the audit work [2]

Core Viewpoint - The company has appointed Liu Jingping as the new General Manager, effective from the date of the board meeting, until the end of the current board's term [1]. Group 1: Appointment Details - The board of directors held a meeting on June 27, 2025, where they approved the appointment of Liu Jingping as General Manager [1]. - Liu Jingping's qualifications were reviewed and deemed compliant with relevant regulations, including the Company Law and the Shanghai Stock Exchange's guidelines [1]. Group 2: Liu Jingping's Background - Liu Jingping, born in 1970, holds a doctoral degree and has extensive experience in the industry [1]. - Previous positions include Chairperson of Hainan Biological Products Company from September 2001 to August 2006, and Executive Director and General Manager of Hainan Kandi Health Industry Investment Co., Ltd. from May 2006 to August 2018 [1]. - Liu has served as the General Manager of the company from February 2016 until March 4, 2025, and currently holds multiple directorships in other companies [1].

Core Viewpoint - ST HuLuWa faces significant governance issues and financial challenges, including delayed performance disclosures and high executive turnover, which have led to regulatory penalties and a decline in revenue from key product lines [1][2][3]. Governance and Compliance Issues - The company was penalized by the Shanghai Stock Exchange for failing to disclose a performance warning within the required timeframe, with a projected loss of 250 million to 280 million yuan for the 2024 fiscal year [1]. - High executive turnover has been a persistent issue, with the resignation of long-term chairman and general manager Liu Jingping and the brief tenure of his successor Zhang Mingrui [2][3]. - Previous compliance failures included warnings issued to the former vice president for insider trading, highlighting significant internal control weaknesses [3]. Financial Performance and Challenges - ST HuLuWa's revenue from digestive system drugs fell by 56.94% year-on-year, while sales expenses remained high, indicating pressure from both pricing strategies and cost fluctuations in raw materials [1][6]. - The company's sales expenses reached 611 million yuan in 2024, accounting for 43% of its revenue, significantly higher than many industry peers [9]. Market Dynamics and Competition - The pediatric medication market is undergoing significant changes, with public hospitals increasing their market share to 50.1% in 2024, while retail pharmacy shares have fluctuated [6]. - Competitors like Kuihua Pharmaceutical and Jichuan Pharmaceutical are rapidly expanding their market presence through unique products and strategic acquisitions [1][8]. R&D and Innovation - ST HuLuWa has 116 projects in development, including several innovative traditional Chinese medicine products, but faces challenges in maintaining sustainable R&D investment [8][9]. - The company reported a 77.79% increase in R&D expenses in 2024, but this trend reversed sharply in the first quarter of 2025, raising concerns about the continuity of its innovation pipeline [9].

证券代码：605199 证券简称：葫芦娃 公告编号：2025-046 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 责令研发部在规定的期限内补充与规范。 2、公司持续组织开展内部控制及各项管理制度的内部自查，进一步强化内控管理。 通过内部协同监督，对公司近期新签订的合同进行了风险排查，严格规范合同签订前的 立项与审批流程。针对研发合同，实行专项立项管理。业务部门签订合同前需提交立项 报告，由财务、法务、研发等多部门组成联合评估小组，对项目必要性、预算合理性及 合规性进行综合评估。在决策审批环节，依据合同金额及性质，分别提交总经理办公会、 董事会或股东大会审议。对于其他类型合同，虽无需立项程序，但仍需遵循分级授权审 批机制。根据合同金额及业务性质，由对应层级管理人员审批，财务、法务部门同步审 核条款合规性与财务风险，确保合同签订规范有序。 3、加强与会计师事务所等外部专业机构的日常沟通，提升公司治理的规范性，提 高公司信息披露质量。 4、公司围绕 ...

中信建投证券股份有限公司 关于海南葫芦娃药业集团股份有限公司 使用闲置募集资金临时补充流动资金的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为海南葫芦娃药业集团股份有限公司（以下简称"葫芦娃"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号——规范 运作》以及《上海证券交易所上市公司自律监管指引第11号——持续督导》等相 关法规和规范性文件的要求，对葫芦娃使用闲置募集资金临时补充流动资金事项 进行了核查，情况如下： 一、募集资金的基本情况 （一）募集资金金额与到账时间 经中国证券监督管理委员会证监许可[2020]1086号文核准，公司向社会公众 公开发行人民币普通股（A股）40,100,000股，发行价格为每股人民币5.19元，募 集资金总额为人民币208,119,000.00元，扣除各项发行费用人民币57,079,347.77 元后的募集资金净额为人民币151,039,652.23元。上述募集资金到位情况业经天 健会计师事务所（特殊普通合伙）审验并出具天健验[2020] ...

证券代码：605199 证券简称：葫芦娃 公告编号：2025-045 海南葫芦娃药业集团股份有限公司 2025 年 6 月 27 日 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于2025年4月27日召开 了第三届董事会第五次会议、第三届监事会第五次会议审议通过了《关于前期会计 差错更正的议案》，同意按照《企业会计准则第28号—会计政策、会计估计变更和 差错更正》、中国证券监督管理委员会《公开发行证券的公司信息披露编报规则第 19号—财务信息的更正及相关披露》和《上海证券交易所股票上市规则》等相关规 定 ， 对 前 期 会 计 差 错 更 正 。 具 体 内 容 详 见 公 司 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）同日披露的《关于前期会计差错更正的公告》（公告编号： 2025-026）。 根据《公开发行证券的公司信息披露编报规则第19 号——财务信息的更正及相 关披露》的相关规定，公司及会计师事务所正在积极推进相关工作，由于此次事项 所涉及的工作量较大，公司无法按原计划完成审计工作。经审慎研究，公司将延期 披露本次会计差错更正后的审计报告。 延期披露期间，公司将持续加 ...